Mincle

Mincle provides engineering platforms that enable precise subcutaneous delivery of biologic therapies through wearable devices, managing pressure, flow rate, and staged volume to ensure full-dose efficiency with minimal dead volume.

Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Subcutaneous delivery of biologic therapies often requires bulky infusion equipment and precise control of pressure, flow rate, and volume, limiting patient mobility and causing dose inefficiencies due to dead volume. Pharmaceutical developers lack integrated platforms to validate and characterize delivery performance in vitro, slowing the development of convenient, high‑efficiency wearable delivery systems.

Solution

Mincle provides engineering platforms that enable precise, adaptive control of subcutaneous biologic delivery through wearable devices. Their HEED (High Efficiency Elastomer Diaphragm) technology manages pressure, flow rate, and staged volume to ensure full‑dose efficiency with minimal dead volume, supporting treatment in home, work, or daily life settings. In parallel, Mincle offers laboratory systems for in‑vitro validation and performance characterization, giving developers confidence in delivery performance before clinical use. The platforms are offered as co‑development opportunities, allowing pharmaceutical and combination‑product teams to integrate the technology into their biologic therapies. This combined hardware and validation approach facilitates the creation of next‑generation, patient‑friendly biologic delivery solutions.

Target Audience

Primary customers are pharmaceutical companies, biologic therapy developers, and combination‑product teams seeking wearable subcutaneous delivery solutions and associated validation tools.

Features

Wearable delivery device with adaptive control of pressure, flow rate, and staged volume for consistent subcutaneous dosing
High Efficiency Elastomer Diaphragm (HEED) architecture that reduces dead volume and ensures full‑dose delivery
Scalable volume range (2–5 mL and 20–60 mL) to accommodate small and large biologic formulations
Integrated patient‑convenient design suitable for home, work, and daily life environments
Co‑development partnership model for pharmaceutical and combination‑product teams
Complementary laboratory systems for in‑vitro validation, performance characterization, and delivery confidence